Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib Dose Escalation Strategy in Adjuvant Therapy for Early High-Risk Breast Cancer
NCT07599137Phase 4Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of abemaciclib in breast cancer, sponsored by Peking University Cancer Hospital & Institute. Planned start May 2026; status: not yet recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07599137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07599137.